Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support COMPASS management team to host an investor conference call today at 1.00pm UK (8.00am ET) London, UK – 9 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care…


Previous articlePT271 – Jeremy Narby, Ph.D. – Anthropology, Ayahuasca, and Plant Teachers
Next articleHow Likely Are Bad Trips and Flashbacks from LSD?